1,3,4‐Thiadiazole Derivatives as VEGFR‐2 Inhibitors and Its Molecular Insight for Cancer Therapy

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis demonstrates potential of 1,3,4-thiadiazole as VEGFR-2 inhibitors in cancer, suggesting improved efficacy and selectivity.

1,3,4‐thiadiazole derivatives effectively inhibit VEGFR‐2, highlighting their potential role in cancer treatment.
Key molecular interactions and structural features enhance their binding to VEGFR‐2, optimizing therapeutic outcomes.
Comprehensive analysis of 151 TDA-based compounds reveals critical substitution patterns and binding sites for enhanced selectivity.
Findings underscore 1,3,4‐thiadiazole's promise for developing next-generation VEGFR‐2 inhibitors with reduced toxicity.

Gawande et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark